San Diego’s Life Sciences Industry - where to next?
Please join LAI and three of San Diego’s most prominent leaders in the life sciences industry for a discussion about the future of the sector in San Diego.
What will be the next exciting company to come out of San Diego’s ecosystem, how will San Diego continue to lead the country and the world in the development of life-changing technologies, and, importantly, as the Torrey Pines Mesa reaches effective capacity, where will this industry look to next for its growth, development, and talent attraction? Our panelists will address these questions and more at our April luncheon event. You won’t want to miss it!
Panelists: John Bonanno, Chief Investment Officer, IQHQ Joseph Panetta, President and CEO, Biocom California
John Bonanno, Chief Investment Officer, IQHQ: John served in various roles at BioMed from 2008 until 2017, most recently serving as its Executive Vice President of Leasing and Development from February 2015 until the sale to Blackstone in January 2016. Prior to BioMed, Mr. Bonanno served as Managing Principal at Corlo, an entrepreneurial real estate investment firm focused on the implementation of fundamental strategies including investment, leasing, repositioning and development. Additionally, Mr. Bonanno co-founded Phase 3 Properties, Inc., a private real estate company specializing in providing real estate solutions to life science companies. As President of Phase 3 Properties from its inception until 2007, Mr. Bonanno participated in the acquisition, development, leasing and management of lab buildings in California, North Carolina and Washington. Mr. Bonanno received his Bachelor of Science Degree in Business Administration from the University of Southern California.
Joseph Panetta, President and CEO, Biocom California: Since 1999, Joseph has been President and CEO and a member of the Board of Directors of Biocom California, the state’s largest and most-experienced leader and advocate for the life science industry. Biocom California works on behalf of over 1,400 members to drive public policy, build an enviable network of industry leaders, create access to capital development, introduce cutting-edge STEM education programs, and create robust value-driven purchasing programs. Mr. Panetta works with an experienced professional staff of 70, with offices located in San Diego, Los Angeles, San Francisco Bay Area, Tokyo, and Washington, D.C, as well as a strong presence in Sacramento. Mr. Panetta is co-founder of the Biocom Political Action Committee; the Biocom Institute for education and workforce development; and the California Biotechnology Foundation, a joint initiative to inform legislators and the media about the life science industry in the state, of which he is Chairman. Since 2014, Mr. Panetta has been a member of the Independent Citizens Oversight Committee, which serves as the governing and oversight board for the California Institute for Regenerative Medicine (CIRM) and is responsible for providing grant funding under the $5.5 billion California Stem Cell Initiative.
Greg McKee, Co-Founder and Managing Director: Torrent Ventures is an early stage California focused digital health and medical technology firm that supports the most promising companies pursing break through solutions in drug development, genomics, diagnostics, medical devices, drug delivery and digital health technologies. Among current roles, Mr. McKee serves as Executive Chairman of Tryp Therapeutics. Previously Mr. McKee was chief executive officer of CONNECT, a start-up accelerator focused on creating and scaling great innovative companies across the life science and technology disciplines. Prior to CONNECT he was chairman, president and chief executive officer of publicly traded Nventa Biopharmacueticals which merged with Akela Pharma. Additionally, he held senior management roles at Valentis, Inc., and Genzyme Corporation, which was acquired by Sanofi for $22 billion. Mr. McKee has lived and worked in Tokyo, Japan, for seven years in investment management (Mizuho Group) during which time he managed $550M in the Japanese equity market, and investment banking (UBS). He also held an appointment as senior advisor to the Former Minister of Foreign Affairs of Japan and speaks fluent Japanese. Mr. McKee has also lived and worked in Singapore for 2 years managing Genzyme’s business units in South East Asia and mainland China.